Compositions for and method of treating acid-base disorders
The present disclosure provides, inter alia, pharmaceutical compositions for and methods of treating an animal, including a human, and methods of preparing such compositions. In certain embodiments, the pharmaceutical compositions contain nonabsorbable pharmaceutical composition and may be used, for example, to treat eubicarbonatemic metabolic acidosis.
1. A method of treating a patient with chronic kidney disease and eubicarbonatemic metabolic acidosis, wherein the patient has a serum bicarbonate value of at least 22 mEq/l prior to the treatment, wherein the method comprises oral administration to the patient in need thereof of a proton-binding crosslinked amine polymer comprising the residue of an amine corresponding to Formula 2 or a salt thereof
wherein
m and n are independently non-negative integers;
R 10 , R 20 , R 30 , and R 40 are independently hydrogen, hydrocarbyl, or substituted hydrocarbyl;
X 1 is
X 2 is hydrocarbyl or substituted hydrocarbyl;
each X 11 is independently hydrogen, hydrocarbyl, substituted hydrocarbyl, hydroxy, or amino;
z is a non-negative number,
the crosslinked amine polymer has an equilibrium swelling ratio in deionized water of 2 or less; and
the crosslinked amine polymer binds a molar ratio of chloride ions to interfering ions of at least 0.35:1, respectively, in an interfering ion buffer at 37° C. wherein the interfering ions are phosphate ions and the interfering ion buffer is a buffered solution at pH 5.5 of 36 mM chloride and 20 mM phosphate.
2. The method of claim 1 wherein the proton-binding crosslinked amine polymer has an equilibrium swelling ratio in deionized water of 1.5 or less.
3. The method of claim 1 wherein the patient is afflicted with eubicarbonatemic metabolic acidosis characterized by a marker of eubicarbonatemic metabolic acidosis selected from the group consisting of urine citrate excretion, urine ammonium excretion, net acid excretion, plasma Endothelin 1, urine Endothelin 1, and plasma aldosterone.
4. The method of claim 1 wherein the method comprises administering a dose of 1-11 grams of said proton-binding crosslinked amine polymer to the patient per day.
5. The method of claim 1 wherein the proton-binding crosslinked amine polymer is a crosslinked aliphatic amine polymer that has been synthesized by first copolymerizing allylamine hydrochloride and N,N′-diallyl-1,3-diaminopropane dihydrochloride to form a copolymer, followed by crosslinking the copolymer with 1,2-dichloroethane.
6. The method of claim 5 wherein the method comprises administering a dose of 1-11 grams of said proton-binding crosslinked amine polymer to the patient per day.
7. The method of claim 6 wherein the proton-binding crosslinked amine polymer has an equilibrium swelling ratio in deionized water of 1.5 or less.